Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

SERTRALINE HCL

All products: general benefit

Other products in the same Health Canada class (N06A, N06AB) — coverage varies; not interchangeable

  • Citalopram (Celexa): general benefit, Not a benefit
  • Escitalopram (Cipralex MELTZ): general benefit, Not a benefit
  • Fluoxetine (Prozac): general benefit, Not a benefit
  • Fluvoxamine (Luvox): general benefit
  • Paroxetine (Paxil): general benefit, Not a benefit
  • Amitriptyline (Elavil): general benefit

17 more in the class list below

Zoloft · DIN 02132702 · 25mg · capsule

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Zoloft (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Zoloft · DIN 02132702 Manufacturer: Upjohn Canada ULC; listing date 1996-10-01 Health Canada: Marketed since 2023-08-22 · brand ZOLOFT · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 25 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1516 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18005 · Verify on the e-Formulary ↗ (DIN 02132702)

Source record
DIN 02132702: Zoloft Raw flags: sec3=Y Item: 281604093; group id 470; item number 1181; lccId None; manufacturer id UJC Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $1.0460; ministry $0.1516 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02132702 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18005
Interchangeable products
AG-Sertraline · DIN 02477882 · $0.1516 Apo-Sertraline · DIN 02238280 · $0.1516 Auro-Sertraline · DIN 02390906 · $0.1516 Co Sertraline · DIN 02287390 · $0.1516 Jamp-Sertraline · DIN 02357143 · $0.1516 M-Sertraline · DIN 02530937 · $0.1516 Mar-Sertraline · DIN 02399415 · $0.1516 Mint-Sertraline · DIN 02402378 · $0.1516 NRA-Sertraline · DIN 02488434 · $0.1516 PMS-Sertraline · DIN 02244838 · $0.1516 Sandoz Sertraline · DIN 02245159 · $0.1516 Sertraline · DIN 02353520 · $0.1516 Sertraline · DIN 02386070 · $0.1516 Sertraline · DIN 02469626 · $0.1516 Teva-Sertraline · DIN 02240485 · $0.1516
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (28:16:04 Antidepressants) and how they are covered

Matched class: 28:16:04 Antidepressants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMITRIPTYLINE, CLOMIPRAMINE HCL, FLUVOXAMINE MALEATE, NORTRIPTYLINE, PHENELZINE SULFATE, TRANYLCYPROMINE SULFATE, VENLAFAXINE HCL, VORTIOXETINE HYDROBROMIDE Some products covered without a code (check the product listing): CITALOPRAM HYDROBROMIDE, DESIPRAMINE, DOXEPIN HCL, DULOXETINE, ESCITALOPRAM, FLUOXETINE HCL, IMIPRAMINE, MIRTAZAPINE, MOCLOBEMIDE, PAROXETINE HCL, TRAZODONE HYDROCHLORIDE, TRIMIPRAMINE 28:16:04 Antidepressants

CITALOPRAM HYDROBROMIDE

· 51 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) · strengths: 10mg, 20mg, 40mg · Tab

ESCITALOPRAM

· 40 products · Listed, not a benefit (2), General benefit (38) · strengths: 10mg, 20mg · Orally Disintegrating Tab, Orally Disintegrating Tablet, Tab

FLUOXETINE HCL

· 41 products · Off-Formulary Interchangeable, not an ODB benefit (17), Listed, not a benefit (2), General benefit (22) · strengths: 10mg, 20mg, 40mg, 60mg, 20mg/5mL · Cap, Oral Sol

FLUVOXAMINE MALEATE

· 6 products · General benefit · strengths: 50mg, 100mg · Tab

PAROXETINE HCL

· 47 products · Off-Formulary Interchangeable, not an ODB benefit (16), General benefit (31) · strengths: 10mg, 20mg, 30mg · Tab

AMITRIPTYLINE

· 12 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CLOMIPRAMINE HCL

· 5 products · General benefit · strengths: 25mg, 50mg, 10mg · Tab

DESIPRAMINE

· 7 products · Listed, not a benefit (4), General benefit (3) · strengths: 25mg, 50mg, 75mg · Tab

DOXEPIN HCL

· 20 products · General benefit (12), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Cap

DULOXETINE

· 38 products · Listed, not a benefit (2), General benefit (36) · strengths: 30mg, 60mg · DR Cap

IMIPRAMINE

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 10mg, 25mg, 50mg · Tab

MIRTAZAPINE

· 25 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 15mg, 30mg, 45mg · Orally Disintegrating Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:04 and 12 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: depressive illness, obsessive-compulsive disorder, panic disorder with or without agoraphobia
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: AMITRIPTYLINE, FLUVOXAMINE MALEATE ALPRAZOLAM · General benefit (6), Off-Formulary Interchangeable, not an ODB benefit (6) Panic Disorder with/without Agoraphobia XANAX and XANAX TS are also indicated for the management of Panic Disorder with or without Agoraphobia. PM: https://pdf.hres.ca/dpd_pm/00070545.PDF; date not captured; DIN 00548359; fetched 2026-09-10 Product monograph AMITRIPTYLINE · General benefit 1 INDICATIONS pms-AMITRIPTYLINE (amitriptyline hydrochloride) is indicated for: • Drug management of depressive illness. PM: https://pdf.hres.ca/dpd_pm/00074345.PDF; date December 11, 1998; DIN 00654507; fetched 2026-09-10 Product monograph CITALOPRAM HYDROBROMIDE · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) Indications CELEXA (citalopram hydrobromide) is indicated for: • the symptomatic relief of depressive illness in adults The relapse rate was significantly lower in CELEXA-treated patients than in placebo-treated patients in two placebo-controlled studies that were conducted over a 24-week period in patients who responded to 6 or 8 weeks of acute treatment with CELEXA (see 14.1 Clinical Trials by Indication). PM: https://pdf.hres.ca/dpd_pm/00082636.PDF; date not captured; DIN 02239607; fetched 2026-09-10 Product monograph FLUOXETINE HCL · Off-Formulary Interchangeable, not an ODB benefit (17), Listed, not a benefit (2), General benefit (22) • Obsessive-Compulsive Disorder (OCD): pms-FLUOXETINE is indicated for the symptomatic treatment of obsessive-compulsive disorder (OCD). PM: https://pdf.hres.ca/dpd_pm/00076968.PDF; date AUG 30, 2024; DIN 02177579; fetched 2026-09-10 Product monograph FLUVOXAMINE MALEATE · General benefit  Obsessive-Compulsive Disorder: PM: https://pdf.hres.ca/dpd_pm/00062197.PDF; date JAN 9, 1991; DIN 01919342; fetched 2026-09-10 Product monograph MIRTAZAPINE · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) 1 INDICATIONS REMERON® (mirtazapine) is indicated for: • the symptomatic relief of depressive illness. PM: https://pdf.hres.ca/dpd_pm/00075141.PDF; date May 4, 2021; DIN 02243910; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS ZOLOFT (sertraline hydrochloride capsules) is indicated for: Adults  Depression ZOLOFT is indicated for the symptomatic relief of depressive illness. However, the antidepressant action of ZOLOFT in hospitalized depressed patients has not been adequately studied. A placebo-controlled European study carried out over 44 weeks, in patients who were responders to ZOLOFT has indicated that ZOLOFT may be useful in continuation treatment, suppressing reemergence of depressive symptoms. However, because of methodological limitations, these findings on continuation treatment have to be considered tentative at this time.  Panic Disorder ZOLOFT is indicated for the symptomatic relief of panic disorder, with or without agoraphobia. The efficacy of ZOLOFT was established in 10-week and 12-week controlled trials of patients with panic disorder as defined according to DSM-III-R criteria. The effectiveness of ZOLOFT in long-term use for the symptomatic relief of panic disorder (i.e., for more than 12 weeks) has not been systematically evaluated in placebo-controlled trials. Therefore, the health professional who el… https://pdf.hres.ca/dpd_pm/00072140.PDF PM date: AUG 22, 2023 Source product: ZOLOFT; DIN 01962779; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.